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Importance: Following major policy changes in the United States, policy makers, clinicians, 
and the general public seek information about whether recreational cannabis use is associated 
with physical health problems later in life. 
Objective: To test associations between cannabis use over twenty years and a variety of physical 
health indices at early midlife.   
Design: A 38-year, prospective, longitudinal study of a representative birth cohort. 
Setting: The Dunedin Multidisciplinary Health and Development Study of New Zealand. 
Participants: The study included 1,037 male and female participants. 
Exposure: We assessed frequency of cannabis use and also cannabis dependence at ages 18, 21, 
26, 32, and 38 years. 
Main Outcomes and Measures: We obtained laboratory measures of physical health 
(periodontal health, lung function, systemic inflammation, and metabolic health), as well as self-
reported physical health, at ages 26 and 38. 
Results: Cannabis use was associated with poorer periodontal health at age 38 and within-
individual decline in periodontal health from age 26-38. For example, 55.61% of those with 15+ 
joint years had periodontal disease, compared with 13.53% of those who never used cannabis.  
Cannabis use was unrelated to other physical health problems, however. Unlike cannabis use, 
tobacco use was associated with worse lung function, systemic inflammation, and metabolic 
health at age 38, as well as within-individual decline in health from age 26 to 38. 
Conclusions and Relevance: Cannabis use for up to 20 years is associated with periodontal 
disease but is not associated with other physical health problems in early midlife. 
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Associations between Cannabis Use and  
Physical Health Problems in Early Midlife:  
A Longitudinal Comparison of Persistent Cannabis versus Tobacco Users 
 Following policy changes in the United States, policy makers, clinicians, and the public 
seek information about whether recreational cannabis use is associated with physical health 
problems later in life. Two recent reviews found that persistent cannabis use is associated with 
relatively few physical health problems, the possible exceptions being cardiovascular risks and 
bronchitis.1,2 Firm conclusions cannot be drawn, however, due to methodological shortcomings.3 
Most studies are cross-sectional and/or rely on self-reported health.4-11 These designs cannot 
resolve the temporal association between cannabis use and health, nor can they address the 
possibility that cannabis users may have biased perceptions of their health. Longitudinal studies 
with laboratory-based measures and physical examinations are needed.  
Few longitudinal studies have characterized cannabis users’ long-term health using 
objective, laboratory-based indices and examinations (Table 1). Each study focused on a single 
domain of physical health, providing an important but incomplete picture. In a population-
representative study of individuals followed from birth to age 38, we tested associations between 
cannabis use over 20 years and multiple domains of physical health in early midlife. We selected 
the following health domains based on prior research,1-3 demonstrated capacity to predict disease 
morbidity and mortality,21-23 and biological plausibility of an effect of cannabis by early midlife: 
periodontal health, lung function, systemic inflammation, and metabolic risk. First, we tested 
whether cannabis use from age 18-38 was associated with age-38 health. Second, we tested 
whether cannabis use from age 26-38 was associated with within-individual health decline using 
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the same measures of health at both ages. To provide a benchmark for comparison, we also 
tested associations between tobacco use and physical health. 
Methods 
Participants 
 Participants are members of the Dunedin Study, a longitudinal investigation of health and 
behavior in a representative birth cohort.24 Study members (N=1,037; 91% of eligible births; 
52% male) were all individuals born between 1972-1973 in Dunedin, New Zealand, who were 
eligible for the longitudinal study based on residence in the province at age 3 and who 
participated in the first follow-up at age 3. The cohort represents the full range of SES in the 
general population of New Zealand’s South Island and is primarily white.24 On adult health, the 
cohort matches the NZ National Health & Nutrition Survey (e.g., body mass index, smoking, 
general practitioner visits).24 Assessments occurred at birth and ages 3, 5, 7, 9, 11, 13, 15, 18, 21, 
26, 32, and, most recently, 38 years, when 95% of the 1,007 living Study members took part. At 
each assessment phase, study members are brought to the Dunedin Research Unit for interviews 
and examinations. The Otago Ethics Committee approved each phase of the study. Written 
consent was obtained from all participants. 
Analyses were limited to 947 study members with age-38 laboratory health data, as 46 
study members were not seen at age 38, 30 were deceased, and 14 had field interviews that did 
not include laboratory measurements/examinations. There were no differences between those 
with and without age-38 health data on childhood health (F=1.42, p=.23), cigarettes smoked per 
day at age 18 (F=1.28, p=.26), or frequency of cannabis use at age 18 (F=2.85, p=.092).  
Table 2 shows characteristics of participants according to tobacco and cannabis 
exposure, including sex, childhood health,25 and childhood SES,26 which were available as 
covariates.  
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Tobacco Pack-Years  
 Cumulative tobacco exposure was calculated from the reported number of cigarettes 
smoked per day at each assessment divided by 20 and multiplied by number of years smoked at 
that rate through age 38. One pack-year reflects the equivalent of 20 cigarettes a day for one 
year. Mean pack-years for those with age-38 health data was 6.17 (SD=8.69). For analyses 
testing associations between pack-years from age 26-38 and change in physical health using the 
same measure of health at both ages, we estimated pack-years in the same way except estimates 
represented cigarette use at ages 26-38 (M=3.30, SD=5.12).  
Cannabis Joint-Years 
 “Pack-years,” which combines information about smoking duration and intensity, is the 
most commonly used exposure in tobacco studies.27 We created a parallel variable that indexes 
cannabis smoking. Cumulative joint-years was estimated using self-reported frequency of 
cannabis use over the past year (0-365 days) at ages 18-38. One joint-year reflects the equivalent 
of daily cannabis use for one year. Mean joint-years between ages 18-38 for those with age-38 
health data was 1.99 (SD=4.43). For analyses of health change from age 26-38, we estimated 
joint-years in the same way except estimates represented cannabis use at ages 26-38 (M=1.18, 
SD=3.00).  
Persistent Cannabis Dependence 
 Because our prior reports have characterized cannabis users in terms of persistent 
dependence over time,28,29 we also report this variable as our exposure. We assessed past-year 
dependence at ages 18-38 with the Diagnostic Interview Schedule30,31 following Diagnostic and 
Statistical Manual of Mental Disorders (DSM) criteria.32,33 Persistent dependence was defined as 
the number of study waves out of five at which a study member met criteria for dependence: 
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never used cannabis at any study wave; used at least once between ages 18-38 but never 
diagnosed; diagnosed at 1 wave; diagnosed at 2 waves; and diagnosed at 3+ waves. For analyses 
of health change from age 26-38, we again defined persistent dependence as the number of study 
waves at which a study member met criteria for dependence but only used cannabis data from 
ages 26-38. 
Age-38 Physical Health  
Physical examinations were conducted during the age-38 assessment day, with blood 
draws between 4:15-4:45 p.m.34 Table 3 describes each health outcome. We report health 
outcomes scored as dichotomous clinical outcomes for clinical relevance and also scored as 
continuously distributed outcomes, because continuous measures are more sensitive to variation. 
Positively skewed continuous outcomes (combined attachment loss, inflammation, triglycerides, 
glycated hemoglobin) were log-transformed prior to analysis.   
Age-26 Physical Health   
The age-38 health measures were also administered at age 26 using the same procedures 
with two exceptions.34 First, periodontal measurements were made using a half-mouth design.12 
Second, serum C-reactive protein was assayed with a sensitivity level of 1 mg/l.45 Due to this 
lower sensitivity, C-reactive protein scores in the top quintile of the distribution were designated 
as elevated.   
Statistical Analysis 
To test whether cannabis use was associated with poor health in early midlife, we tested 
the bivariate association between cannabis use from age 18-38 and age-38 health (Table 4, 
Model 1) and subsequently added tobacco pack-years from age 18-38 as a covariate (Table 4, 
Model 2). To test whether cannabis use from age 26-38 was associated with health decline using 
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the same measure of health at both ages, we tested the bivariate association between cannabis use 
from age 26-38 and age-38 health (Table 5, Model 1) and subsequently added age-26 health as a 
covariate (Table 5, Model 2), followed by tobacco pack-years from age 26-38 as an additional 
covariate (Table 5, Model 3). All analyses controlled for sex. 
Statistical analyses tested associations of tobacco pack-years (a continuous variable), 
cannabis joint-years (a continuous variable), and cannabis dependence (a 5-level ordinal 
variable) with both dichotomous and continuous health outcomes. We analyzed dichotomous 
outcomes using Poisson regression models to derive relative risks and continuous outcomes 
using ordinary-least-squares regression to derive beta coefficients. We standardized continuous 
variables prior to conducting statistical tests. Therefore, relative risks and beta coefficients can 
be interpreted as the increase in risk of the outcome, given a 1 SD increase in pack-years or joint-
years. To aid interpretation of relative risks and beta coefficients associated with continuous 
pack-years and joint-years, we report unstandardized, sex-adjusted means for health outcomes as 
a function of tobacco and cannabis use, with study members grouped according to pack-years 
and joint-years in 5-year increments (Table 4).  
Results 
Tobacco Smoking and Health  
Bivariate associations showed that tobacco pack-years was associated with worse health 
for eight of twelve health outcomes (both categorically- and continuously-scored versions of the 
following): periodontal health, lung function, inflammation, metabolic syndrome, high density 
lipoprotein, triglycerides, HbA1c, and self-reported health (Table 4, Model 1). For example, 
12.26% of individuals who never used tobacco had periodontal disease (1+ sites with >5mm 
attachment loss), compared with 52.89% of individuals with 15+ pack-years (Table 4). 
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Statistical tests showed that for every standard deviation increase in pack-years (~9 pack-years), 
relative risk for periodontal disease increased by 1.63 (p<.001). Associations remained 
significant for all eight of these health outcomes after controlling for cannabis joint-years (Table 
4, Model 2) and after additionally controlling for childhood health and SES (when considering 
either the continuous or categorical version of the outcome) (Supplemental Table 1, Model 3). 
Findings are consistent with prior research.12-14,18,46-51  
Cannabis Use and Health  
Bivariate associations showed that cannabis joint-years was associated with worse health 
for three of twelve health outcomes (either the continuous or categorical version of the outcome): 
periodontal health, lung function, self-reported health (Table 4, Model 1). Adverse associations 
remained significant for two outcomes (periodontal health, lung function) after controlling for 
tobacco pack-years (Table 4, Model 2) and after additionally controlling for childhood health 
and SES (Supplemental Table 1, Model 3). However, poorer lung function (FEV1/FVC) among 
cannabis users was probably not indicative of airway obstruction, as joint-years (unlike tobacco 
pack-years) was unrelated to reduced FEV1 (Supplemental Table 2). Rather, reduced 
FEV1/FVC among cannabis users was attributable to higher FVC values. It is unclear whether 
higher FVC values reflect better health. 
Unlike tobacco, cannabis joint-years was associated with slightly smaller waist 
circumference and lower BMI. Further, after adjusting for tobacco pack-years (Table 4, Model 
2), associations emerged between joint-years and better HDL, triglycerides, and glycated 
hemoglobin. Joint-years was not associated with lower risk of metabolic syndrome, however.  
Results for persistent cannabis dependence (and results for persistent regular cannabis 
use, Supplemental Table 3) were nearly identical to those for joint-years. Bivariate associations 
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showed that persistent dependence was associated with worse health for three of twelve 
outcomes (continuous or categorical): periodontal health, lung function, self-reported health. 
Associations remained significant for one of those three (periodontal health) after controlling for 
tobacco pack-years (Table 4, Model 2) and after additionally controlling for childhood health 
and SES (Supplemental Table 1, Model 3). Supplemental Table 4 provides a descriptive 
summary of the aforementioned findings.  
Periodontal health was the only aspect of health that showed a robust adverse association 
in analyses of both persistent dependence and joint-years. Post-hoc analyses showed that 
cannabis users brushed and flossed less than others, and were more likely to be alcohol 
dependent (Supplemental Table 5). However, associations between cannabis use and poor 
periodontal health remained significant after controlling for tobacco pack-years, childhood health 
and SES, brushing and flossing, and alcohol dependence (Supplemental Table 6).   
The general lack of association between persistent cannabis use and poor physical health 
may surprise. One explanation is that healthy youth select into cannabis use. Our test showed no 
correlation between cannabis use and childhood health (Table 2). Another explanation is 
cannabis users may have healthier adult lifestyles. Tests showed that cannabis was not associated 
with more physical activity or with a diet of fruits and vegetables (Supplemental Table 5). The 
lacking associations between cannabis use and poor physical midlife health could not be 
attributed to better initial health, more physical activity, better diet, or less alcohol abuse. 
Tobacco and Cannabis Use and Change in Health  
 Tobacco pack-years from age 26-38 was associated with worsening periodontal health, 
lung function, systemic inflammation, and metabolic health (Table 5, Model 2). For example, 
pack-years from age 26-38 was associated with increased risk of age-38 metabolic syndrome 
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after accounting for age-26 metabolic syndrome (Table 5, Model 2: RR=1.18, p=.021). Tobacco 
users also self-reported worse health at 38, and this association persisted after accounting for 
age-26 self-reported health (Table 5, Model 2).  
Like tobacco use, cannabis use was associated with decline in periodontal health and lung 
function (measured continuously) (Table 5, Model 2), even after accounting for tobacco pack-
years from 26-38 (Table 5, Model 3). Again, however, decline in FEV1/FVC was probably not 
attributable to airway obstruction, as cannabis use was not robustly associated with decline in 
FEV1 (Supplemental Table 7). Cannabis use was not associated with deteriorating health in 
other domains. 
Discussion 
Findings showed that, in general, cannabis use over 20 years was unrelated to health 
problems in early midlife. Across several domains of health (periodontal, lung function, 
inflammation, and metabolic health), clear evidence of an adverse association with cannabis use 
was apparent for only one: periodontal health. Cannabis use from age 26-38 was not associated 
with within-individual health decline during this 12-year period, with the exception of 
periodontal health. By comparison, tobacco use was associated with worse periodontal health, 
lung function, systemic inflammation, HDL, triglycerides, and glucose control in early midlife, 
as well as health decline from age 26-38.  
Findings showed that cannabis use was associated with slightly better metabolic health 
(smaller waist circumference, lower BMI, better lipid profiles and glucose control). The majority 
of these associations emerged only after controlling for tobacco use, however. Effects were small 
but intriguing given similar reports from cross-sectional studies,4,8,9,52-54 and that 
endocannabinoids appear to be involved in the regulation of metabolism.55 Several studies have 
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shown that overweight patients who took a synthetic cannabinoid-1 receptor blocker, 
rimonabant, evidenced reduced waist circumference and improved lipid profiles.56,57 It is unclear, 
however, if and how recreational cannabis use (and plant-based cannabinoids) might impact 
metabolic health. Cannabinoid pharmacology is more complex than commonly believed,58 and 
biological arguments can be made for cannabis-related worsening or improvement of metabolic 
health.9,59 The only other longitudinal study to characterize cannabis users’ metabolic health 
found no association,19 and our finding of a small association mainly emerged after controlling 
for tobacco use. Moreover, cannabis use was not associated with reduced risk of metabolic 
syndrome. Thus, current evidence suggests that recreational cannabis use is unlikely to improve 
metabolic health in the general population.    
In at least two instances, we found no association between cannabis and poor health when 
we might have expected one. In the first instance, we found no association between cannabis and 
reduced FEV1 (Supplemental Table 3), which is somewhat puzzling given that tobacco use is 
associated with reduced FEV1.
13,14 An association between cannabis and reduced FEV1 could 
emerge with greater exposure to cannabis.13 Nonetheless, given no evidence of reduced FEV1 
among cannabis users, our finding of lower FEV1/FVC among cannabis users probably did not 
indicate airway obstruction. Rather, reduced FEV1/FVC appeared to reflect cannabis users’ 
slightly larger forced vital capacity (FVC). This association with larger FVC, also reported 
elsewhere,13 is not understood. Overall, findings are consistent with a recent review that 
concluded that there is little evidence that cannabis affects FEV1 and airway obstruction.
60 In the 
second surprising instance, we found no association between cannabis and cardiovascular risks 
(e.g., high blood pressure, worse cholesterol), which may appear at-odds with evidence that 
cannabis use increases risk for cardiovascular complications,61-63 even among young healthy 
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individuals.64 Our somewhat disparate findings are reconciled by evidence that cannabis-related 
cardiovascular complications are likely acute cannabis effects.19,53,61,63 
Although we found that cannabis users were generally no worse off than non-users on 
nearly all health indices, they did have worse periodontal health. Cannabis use was associated 
with attachment loss, which can result in tooth loss.12,51 A similar association was observed for 
tobacco use, consistent with previous research.12,51,65 Tobacco’s effect on periodontal disease is 
thought to be mediated through increased inflammation and vasoconstriction,65 which may or 
may not be the case for cannabis. Cannabis use was not associated with systemic inflammation 
here or elsewhere,18,54 but prior research has shown that cannabis can induce 
vasoconstriction.66,67 
This study has limitations. First, cannabis joint-years was based on self-reports collected 
at ages 18-38. Validation of cannabis use through laboratory measures could have helped detect 
cannabis users who denied use. Underreporting due to reluctance to admit to illegal drug use is 
unlikely, however, because study members, interviewed repeatedly over the course of their lives, 
have learned to trust our confidentiality guarantee. Second, disentangling cannabis and tobacco 
use is challenging. In New Zealand, cannabis is not typically mixed with tobacco,10 but most 
participants who used cannabis also smoked cigarettes. Although we controlled for tobacco use, 
imperfect control might bias results toward finding spurious associations between cannabis use 
and poor health. We note, however, that all poor health outcomes, apart from periodontal 
disease, were unrelated to cannabis use. Third, our findings are based on a single New Zealand 
cohort who began using cannabis in the 1980s-90s. Although our findings are generally 
consistent with longitudinal studies of United States samples (Table 1), tetrahydrocannabinol 
(THC; the primary psychoactive ingredient in cannabis) content has increased since then.2 If 
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health associations are mediated by THC, we may have underestimated the cannabis-health 
association. Fourth, our conclusions are limited to a specific set of health problems assessed in 
early midlife. Though this is the most comprehensive study to date, cannabis use may be 
associated with health problems not studied here or that tend to emerge later in life, such as 
cancer. Fifth, we compared findings for cannabis against findings for tobacco. Our intent in 
doing so was to allay concerns that our study’s methods might be unable to detect health 
problems. We acknowledge that participants acquired more tobacco pack-years than cannabis 
joint-years, with most cannabis users using for fewer than five years. Greater tobacco exposure 
may explain health decline associated with tobacco but not cannabis use. If patterns of cannabis 
use shift, and more users begin to use cannabis as they do tobacco (i.e., multiple joints per day), 
cannabis-associated health problems might emerge. Finally, our study cannot comment on the 
health effects of cannabis in older adults or the safety of medical marijuana use in patients who 
are already unwell. 
This study has a number of implications. First, cannabis use for up to 20 years is not 
associated with a specific set of physical health problems in early midlife. The sole exception is 
that cannabis use is associated with periodontal disease. Second, cannabis use for up to 20 years 
is not associated with net metabolic benefits (i.e., lower rates of metabolic syndrome). Third, 
results should be interpreted in the context of prior research showing that cannabis use is 
associated with accidents and injuries, bronchitis, acute cardiovascular events, and, possibly, 
infectious diseases and cancer, as well as poor psychosocial and mental health outcomes.1-
3,20,28,29,60,68-70
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Table 1. Longitudinal studies with objective, laboratory-based indices and physical examinations of cannabis users’ long-term 
physical health.  
      
Study Analysis Sample 
Age (or Age 
Range) at 
Baseline 
Age (or Age 
Range) at 
Follow-up Outcomes Finding 
      
Periodontal Health 
      
Thomson et al.12 Dunedin 
Multidisciplinary 
Health and 
Development 
Study: 903 men 
and women 
18 32 Periodontal 
attachment loss 
Cannabis use was associated 
with attachment loss, even 
after adjusting for tobacco 
use, sex, SES, dental service 
use, and plaque. 
      
Lung Functiona 
      
Pletcher et al.13 Coronary Artery 
Risk 
Development in 
Young Adults 
(CARDIA): 
5,016 men and 
women 
18-30 (M=25) Participants were 
followed up to 20 
years from 
baseline 
Forced expiratory 
volume (FEV1) and 
forced vital capacity 
(FVC) 
In adjusted analyses 
(covariates included, but 
were not limited to, 
demographic factors and 
tobacco exposure), there was 
a non-linear association of 
cannabis exposure with 
FEV1 and FVC. At low 
levels of cannabis exposure, 
FEV1 and FVC increased. At 
higher levels of cannabis 
exposure, associations 
reversed (FEV1) or leveled 
(FVC). 
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Table 1 Continued.  
      
Study Analysis Sample 
Age (or Age 
Range) at 
Baseline 
Age (or Age 
Range) at 
Follow-up Outcomes Finding 
      
Hancox et al.14 Dunedin 
Multidisciplinary 
Health and 
Development 
Study: 779 men 
and women 
15 32 Forced expiratory 
volume (FEV1), 
forced vital capacity 
(FVC), and airflow 
obstruction 
(FEV1/FVC) 
In adjusted analyses 
(covariates included, but 
were not limited to, 
demographic factors, 
tobacco use, and baseline 
level of the outcome), 
cannabis use was associated 
with higher FVC but was not 
associated with FEV1 or 
FEV1/FVC. 
      
Taylor et al.15 Dunedin 
Multidisciplinary 
Health and 
Development 
Study: 859-930 
men and women 
18 26 Forced expiratory 
volume (FEV1) and 
airflow obstruction 
(FEV1/FVC) 
In adjusted models 
(covariates included, but 
were not limited to 
demographic factors and 
tobacco use), cannabis 
exposure was associated 
with reduced FEV1 but was 
not associated with 
FEV1/FVC.  
      
Tashkin et al.16 255 men and 
women 
M=33 Up to 8 years 
from baseline 
Forced expiratory 
volume (FEV1) 
Cannabis use was not 
associated with decline in 
FEV1. 
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Table 1 Continued. 
      
Study Analysis Sample 
Age (or Age 
Range) at 
Baseline 
Age (or Age 
Range) at 
Follow-up Outcomes Finding 
      
Sherrill et al.17  Tucson 
longitudinal 
study of airways 
obstructive 
disease: 856 men 
and women with 
pulmonary data 
from at least two 
assessments 
15-60 Up to 6 years 
from baseline 
Forced expiratory 
volume (FEV1) and 
airflow obstruction 
(FEV1/FVC) 
In adjusted models 
(covariates included, but 
were not limited to, 
demographic factors), 
previous cannabis use was 
associated with reduced 
FEV1 and FEV1/FVC, 
whereas current cannabis use 
was associated with a non-
significant increase in FEV1 
and was not associated with 
FEV1/FVC. 
      
Systemic Inflammation 
      
Costello et al.18 Great Smoky 
Mountains 
Study: 1334 
boys and girls 
9-16 21 C-reactive protein  Cannabis use was not 
associated with later C-
reactive protein, controlling 
for past C-reactive protein. 
C-reactive protein predicted 
later cannabis use and 
cannabis use disorder 
controlling for previous 
cannabis use and cannabis 
use disorder, but not after 
controlling for age, sex, race, 
body mass index, SES, 
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health, medications, and 
psychiatric disorder.  
      
Table 1 Continued.  
      
Study Analysis Sample 
Age (or Age 
Range) at 
Baseline 
Age (or Age 
Range) at 
Follow-up Outcomes Finding 
      
      
Metabolic Health 
      
Rodondi et al.19 Coronary Artery 
Risk 
Development in 
Young Adults 
(CARDIA): 
3,617 men and 
women 
18-30 Participants were 
followed to 15 
years from 
baseline. 
Body mass index, 
waist 
circumference, 
systolic and 
diastolic blood 
pressure, total 
cholesterol, high-
density lipoprotein 
(HDL) cholesterol, 
triglycerides, 
fasting plasma 
glucose  
In unadjusted analyses, 
cannabis use was associated 
with larger waist 
circumference, higher 
systolic blood pressure, and 
higher triglycerides. In 
adjusted analyses (covariates 
included, but were not 
limited to, demographic 
factors; tobacco, alcohol, 
and illicit drug use; and 
baseline level of the 
outcome variable), all 
associations became non-
significant. 
Note. aWe report on spirometry measures (FEV1, FVC, and FEV1/FVC ratio). These are the most commonly reported measures of 
lung function in longitudinal studies, and FEV1/FVC is the most sensitive measure for assessing airway remodeling in a large 
cohort. A few longitudinal studies of cannabis also included other measures of respiratory health. For a recent report from the 
Dunedin Study on cannabis and respiratory symptoms (e.g., morning cough, sputum production, wheeze), see Hancox et al.20  
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Table 2. Characteristics of study members according to tobacco and cannabis use from age 18 to 38 years.   
        
 Tobacco Pack-Years (Ages 18-38)a 
 % or Mean (SD) as a Function of Pack-Years Statistical Testsb 
   
 Never Used <5y 5 to <10y 10 to <15y 15+y   
Correlate N=461 N=137 N=83 N=92 N=172 r p 
        
Sex (% Male) 52% 39% 42% 50% 58% 0.07 0.034 
        
Childhood Healthc 0.04 (0.97) 0.03 (0.86) 0.10 (1.00) 0.05 (0.89) -0.15 (1.02) -0.07 0.045 
        
Childhood SESc 0.17 (0.98) 0.15 (0.97) 0.01 (0.87) -0.33 (0.90) -0.29 (1.03) -0.20 <.001 
        
Cannabis Joint-Years Age 18 to 38 0.61 (2.39) 1.28 (3.17) 2.04 (3.82) 2.67 (4.35) 5.84 (6.83) 0.48 <.001 
        
Tobacco Pack-Years Age 18 to 38 0.00 (0.00) 2.25 (1.65) 7.44 (1.38) 12.50 (1.50) 21.82 (5.40) - - 
        
 Cannabis Joint-Years (Ages 18-38)a 
 % or Mean (SD) as a Function of Joint-Years Statistical Testsb 
   
 Never Used <5y 5 to <10y 10 to <15y 15+y   
Correlate N=265 N=552 N=42 N=44 N=37 r p 
        
Sex (% Male) 38% 50% 71% 73% 78% 0.21 <.001 
        
Childhood Healthc 0.01 (0.92) 0.03 (0.97) 0.03 (0.98) 0.01 (0.90) -0.07 (0.94) -0.02 .61 
        
Childhood SESc 0.05 (1.01) 0.10 (0.99) -0.19 (0.93) -0.34 (0.85) -0.42 (0.96) -0.13 <.001 
        
Cannabis Joint-Years Age 18 to 38 0.00 (0.00) 0.63 (1.05) 7.38 (1.27) 12.54 (1.43) 17.83 (2.13) - - 
        
Tobacco Pack-Years Age 18 to 38 1.97 (5.27) 6.07 (7.84) 12.63 (9.95) 16.34 (8.86) 19.34 (11.96) 0.48 <.001 
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Table 2 Continued.  
        
 Persistent Cannabis Dependence (Ages 18-38)a 
 % or Mean (SD) as a Function of Persistence of Cannabis Dependence Statistical Testsb 
   
 Never Used Used, No Dx 1 Dx 2 Dx 3+ Dx   
Correlate N=265 N=504 N=85 N=43 N=43 r p 
        
Sex (% Male) 38% 49% 69% 65% 84% 0.22 <.001 
        
Childhood Healthc 0.01 (0.92) 0.03 (0.98) 0.02 (0.91) -0.09 (0.96) 0.11 (0.89) 0.01 .82 
        
Childhood SESc 0.05 (1.01) 0.09 (0.98) -0.12 (1.03) -0.13 (0.99) -0.40 (0.86) -0.10 .004 
        
Cannabis Joint-Years Age 18 to 38 0 0.92 (2.37) 4.80 (5.66) 9.32 (5.36) 13.94 (4.70) 0.72 <.001 
        
Tobacco Pack-Years Age 18 to 38 1.97 (5.27) 5.84 (7.76) 9.64 (9.33) 15.52 (9.22) 20.58 (10.05) 0.51 <.001 
Note. a. Of the N=947 with age-38 health data, two study members were missing tobacco pack-years data, and seven study members were 
missing cannabis joint-years data. b. We report Pearson correlations between correlates and tobacco pack-years (a continuous variable), 
cannabis joint-years (a continuous variable), and persistent cannabis dependence (a 5-level variable). c. Scores were standardized to M=0.00, 
SD=1.00. Children’s overall health at ages 3, 5, 7, 9, 11, 13, and 15 years was rated by two Dunedin Research Unit staff members based on 
review of birth records and assessment dossiers, including clinical assessments and reports of infections, diseases, injuries, hospitalizations, and 
other health problems collected during standardized maternal interviews. Ratings used a 5-point scale (inter-rater agreement 0.85). SES 
(socioeconomic status) was defined as the average highest occupational status level of either parent across study assessments (1=unskilled 
laborer; 6=professional), from the study member’s birth through 15 years, on New Zealand’s occupational rating of the 1970s.  
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Table 3. Physical Health Measures at Age 38.  
    
Measure Description of Measure  
Continuous 
Outcome: Mean 
and Standard 
Deviation 
Dichotomous Outcome: 
Clinical Cutoffs and 
Prevalence for 
Females, Males 
    
    
Periodontal Health Examinations were conducted in all 4 quadrants using calibrated dental 
examiners; 3 sites (mesiobuccal, buccal, and distolingual) per tooth were 
examined, and gingival recession (the distance in millimeters from the 
cemento-enamel junction to the gingival margin) and probing depth (the 
distance from the gingival margin to the base of the pocket) were recorded 
using a PCP-2 probe. The attachment loss for each site was computed by 
summing gingival recession and probing depth (third molars were not 
included).  
Mean attachment 
loss across all 
sites (combined 
attachment loss 
in millimeters): 
M=1.61, 
SD=0.74 
Periodontal Disease: 1+ 
site(s) with 5 or more 
mm of attachment 
loss;12 18%, 28% 
    
    
Lung Function Spirometry was performed before and after 200 mcg salbutamol inhaled via 
large-volume spacer. The best FEV1 (forced expiratory volume) and FVC 
(forced vital capacity) values from three acceptable and reproducible 
maneuvers were used.35  
 
Post-
bronchodilator 
FEV1/FVC ratio 
after 200 mg 
salbutamol: 
M=79.95, 
SD=6.46 
Chronic obstructive 
pulmonary disease 
(airflow obstruction): 
FEV1/FVC ratio < 
0.70;36 5%, 9% 
    
Systemic Inflammation Elevation in inflammation was assessed by assaying high-sensitivity C-
reactive protein (mg/L). C-reactive protein level is thought to be one of the 
most reliable measured indicators of vascular inflammation and has been 
recently endorsed as an adjunct to traditional risk factor screening for 
cardiovascular risk. High-sensitivity C-reactive protein was measured on a 
Modular P analyzer (Roche Diagnostics, GmbH, D-68298, Mannheim, 
Germany) using a particle-enhanced immunoturbidimetric assay.  
C-Reactive 
Protein Level 
(mg/L): M=2.43, 
SD=3.82 
High C-reactive 
Protein: > 3 mg/L;37 
26%, 15% 
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Table 3 Continued. 
    
Measure Description of Measure  
Continuous 
Outcome: Mean 
and Standard 
Deviation 
Dichotomous Outcome: 
Clinical Cutoffs and 
Prevalence for 
Females, Males 
    
Metabolic Syndrome Metabolic syndrome was assessed with five risk factor biomarkers: (i) high 
waist circumference, (ii) low high density lipoprotein cholesterol, (iii) high 
triglycerides, (iv) high blood pressure, and (v) high glycated hemoglobin. 
Study members with 3+ risk factors were defined as having the metabolic 
syndrome, per ATPIII guidelines 
(http://www.nhlbi.nih.gov/files/docs/guidelines/atglance.pdf).39 Dichotomous 
clinical cutoffs for the five biomarkers for metabolic syndrome are provided 
below. 
 
- Metabolic Syndrome: 
3+ risks; 11%, 21% 
    
Waist Circumference Waist circumference (in centimeters).  Waist 
circumference in 
centimeters: 
M=86.41, 
SD=12.65 
High Waist 
Circumference 
(Biomarker for 
Metabolic Syndrome):  
>88 cm for women or > 
102 cm for men; 25%, 
16%a 
    
High Density Lipoprotein 
(HDL)  
Measured via blood in units of mmol/L using colorimetric assay on a Modular 
P analyzer.  
HDL level 
(mmol/L): 
M=1.44, 
SD=0.42 
Low HDL (Biomarker 
for Metabolic 
Syndrome): ˂1.3 
mmol/L (50 mg/dL)  
for women or ˂ 1.04 
mmol/L (40 mg/dL) for 
men; 25%, 26%a,b 
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Table 3 Continued. 
    
Measure Description of Measure  
Continuous 
Outcome: Mean 
and Standard 
Deviation 
Dichotomous Outcome: 
Clinical Cutoffs and 
Prevalence for 
Females, Males 
    
    
Triglyceride  Measured via blood in units of mmol/L using colorimetric assay on a Modular 
P analyzer. 
Triglyceride 
level (mmol/L): 
M=2.06, 
SD=1.45 
High Triglycerides 
(Biomarker for 
Metabolic Syndrome): 
≥2.26 mmol/L (200 
mg/dL); 14%, 50%a,b 
    
Blood Pressure Assessed according to standard protocols with a Hawksley random-zero 
sphygmomanometer with a constant deflation valve.38  
Systolic: 
M=120.26, 
SD=12.14; 
Diastolic: 
M=78.16, 
SD=9.93 
High Blood Pressure 
(Biomarker for 
Metabolic Syndrome): 
≥ 130 mm Hg for 
systolic or ≥ 85 mm Hg 
for diastolic; 16%, 
38%a 
    
Glycated Hemoglobin 
Concentration (HbA1c) 
Glycated hemoglobin concentrations (expressed as a percentage of total 
hemoglobin) were measured by ion exchange high-performance liquid 
chromatography (Variant II; Bio-Rad, Hercules, CA) (coefficient of variation, 
2.4%), a method certified by the U.S. National Glycohemoglobin 
Standardization Program (NGSP; http://www.ngsp.org/). 
HbA1c (% of 
total 
hemoglobin): 
M=5.41, 
SD=0.54 
High Glycated 
Hemoglobin 
(Biomarker for 
Metabolic Syndrome): 
Scores ≥ 5.7%; 14%, 
23%c 
    
Body Mass Index (BMI) Height was measured to the nearest millimeter using a portable Harpenden 
Stadiometer (Holtain, Crymych, United Kingdom). Weight was recorded to 
the nearest 0.1 kg using calibrated scales. Body mass index was measured as 
weight in kilograms divided by height in meters squared.  
BMI: M=27.19, 
SD=5.31 
Obese: BMI ≥ 30; 25%, 
23% 
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Table 3 Continued. 
    
Measure Description of Measure  
Continuous 
Outcome: Mean 
and Standard 
Deviation 
Dichotomous Outcome: 
Clinical Cutoffs and 
Prevalence for 
Females, Males 
    
Self-Reported Health Study members were asked: “In general, would you say your health is 
excellent, very good, good, fair, or poor?” Responses range from 5=excellent, 
to 1=poor. 
Self-Reported 
Health Mean 
Rating: M=3.82, 
SD=0.85 
Bad Health: Self 
ratings of fair or poor 
health; 5%, 8% 
Note. aOn the basis of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood 
Cholesterol in Adults (Adult Treatment Panel III). See http://www.nhlbi.nih.gov/files/docs/guidelines/atglance.pdf bWe controlled the diets of all study 
members and obtained non-fasting lipids. Recent research suggests that fasting is unnecessary for lipids tests.40-44 We used the American Heart 
Association’s recommended cutoff of 200 mg/dL for non-fasting triglycerides. cOn the basis of the NGSP clinical advisory committee 2010 
recommendation. See http://www.ngsp.org/cac2010.asp 
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Table 4. Associations of tobacco and cannabis use from age 18 to 38 with age 38 physical health measures. 
             
  
 Statistical Testsc 
  
% or Mean  
As a Function  
of Use, Adjusted for Sexb Model 1d: Bivariate 
Model 2d: + Control for Pack-
Years (or Joint-Years) 
Age 38 Healtha Predictor 
Never 
Used 
<5 y/ 
No Dx 
5 to 
<10 y/ 
1 Dx 
10 to 
<15 y/ 
2 Dx 
15+y/ 
3+ Dx 
(RR or 
β) 95% CI p 
(RR or 
β) 95% CI p 
             
A. Periodontal 
Health 
 
     
      
             
Categorical:
% with 1+ 
Sites of 
>5mm 
Attachment 
Loss 
Pack-years 12.26 16.00 20.74 36.29 52.89 1.63 1.51, 1.77 <.001 1.53 1.38, 1.70 <.001 
            
Joint-Years 13.53 21.21 51.45 51.23 55.61 1.36 1.27, 1.46 <.001 1.11 1.02, 1.22 .020 
            
Cannabis 
Dependence 
13.53 21.30 32.62 47.89 59.72 1.44 1.32, 1.57 <.001 1.13 1.02, 1.26 .024 
             
Continuous: 
Mean 
Attachment 
Loss Across 
Sites (mm) 
Pack-years 1.37 1.44 1.63 1.79 2.32 0.50 0.45, 0.56 <.001 0.45 0.38, 0.51 <.001 
            
Joint-Years 1.41 1.57 2.08 2.21 2.51 0.33 0.26, 0.39 <.001 0.12 0.05, 0.18 <.001 
            
Cannabis 
Dependence 
1.41 1.57 1.75 2.06 2.58 0.33 0.27, 0.39 <.001 0.09 0.02, 0.16 .011 
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Table 4 Continued. 
             
  
 Statistical Testsc 
  
% or Mean  
As a Function  
of Use, Adjusted for Sexb Model 1d: Bivariate 
Model 2d: + Control for Pack-
Years (or Joint-Years) 
Age 38 Healtha Predictor 
Never 
Used 
<5 y/ 
No Dx 
5 to 
<10 y/ 
1 Dx 
10 to 
<15 y/ 
2 Dx 
15+y/ 
3+ Dx 
(RR or 
β) 95% CI p 
(RR or 
β) 95% CI p 
             
B. Lung 
Function 
 
     
      
             
Categorical:
% with 
COPD 
(FEV1/FVC     
< 70) 
Pack-years 5.06 7.93 6.54 7.80 10.55 1.30 1.06, 1.59 .010 1.26 1.01, 1.56 .038 
            
Joint-Years 5.26 6.81 11.33 10.81 9.75 1.18 0.98, 1.42 .075 1.06 0.87, 1.29 .58 
            
Cannabis 
Dependence 
5.24 6.68 9.05 9.01 12.73 1.23 1.00, 1.52 .053 1.09 0.85, 1.40 .48 
             
Continuous:
FEV1/FVC
±  
Pack-years 80.98 79.74 79.78 79.67 77.58 -0.19 -0.26, -0.13 <.001 -0.15 -0.22, -0.08 <.001 
            
Joint-Years 80.72 80.15 77.95 78.09 76.43 -0.17 -0.23, -0.11 <.001 -0.10 -0.17, -0.02 .010 
            
Cannabis 
Dependence 
80.72 80.17 78.93 78.47 76.47 -0.15 -0.22, -0.08 <.001 -0.06 -0.14, 0.01 .106 
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Table 4 Continued. 
             
  
 Statistical Testsc 
  
% or Mean  
As a Function  
of Use, Adjusted for Sexb Model 1d: Bivariate 
Model 2d: + Control for Pack-
Years (or Joint-Years) 
Age 38 Healtha Predictor 
Never 
Used 
<5 y/ 
No Dx 
5 to 
<10 y/ 
1 Dx 
10 to 
<15 y/ 
2 Dx 
15+y/ 
3+ Dx 
(RR or 
β) 95% CI p 
(RR or 
β) 95% CI p 
             
C. Systemic 
Inflammation 
 
     
      
             
Categorical:
% with High 
C-Reactive 
Protein (>3 
mg/L) 
Pack-years 18.41 13.94 33.36 17.66 27.93 1.17 1.04, 1.31 .007 1.16 1.02, 1.32 .023 
            
Joint-Years 20.26 19.66 24.95 30.90 22.02 1.09 0.97, 1.23 .145 1.01 0.88, 1.16 .88 
            
Cannabis 
Dependence 
20.26 19.60 22.66 29.53 22.96 1.08 0.95, 1.23 .26 0.98 0.85, 1.13 .79 
             
Continuous: 
C-Reactive 
Protein Level 
(mg/L) 
Pack-years 2.32 1.70 3.20 2.05 3.17 0.12 0.05, 0.18 <.001 0.12 0.04, 0.19 .002 
            
Joint-Years 2.48 2.33 2.09 4.01 2.28 0.06 -0.01, 0.13 .073 0.00 -0.07, 0.08 .95 
            
Cannabis 
Dependence 
2.48 2.36 2.24 3.24 2.64 0.04 -0.02, 0.11 .21 -0.03 -0.11, 0.05 .46 
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Table 4 Continued. 
             
  
 Statistical Testsc 
  
% or Mean  
As a Function  
of Use, Adjusted for Sexb Model 1d: Bivariate 
Model 2d: + Control for Pack-
Years (or Joint-Years) 
Age 38 Healtha Predictor 
Never 
Used 
<5 y/ 
No Dx 
5 to 
<10 y/ 
1 Dx 
10 to 
<15 y/ 
2 Dx 
15+y/ 
3+ Dx 
(RR or 
β) 95% CI p 
(RR or 
β) 95% CI p 
             
D. Metabolic 
Health 
 
     
      
Categorical:             
% with 
Metabolic 
Syndrome 
Pack-years 14.32 13.12 15.86 15.16 23.16 1.18 1.04, 1.35 .012 1.24 1.06, 1.45 .006 
            
Joint-Years 18.91 14.23 15.38 21.79 13.53 1.01 0.88, 1.16 .94 0.90 0.76, 1.07 .23 
            
Cannabis 
Dependence 18.88 13.27 19.49 26.54 10.99 
0.99 0.85, 1.15 .88 0.86 0.73, 1.02 .092 
Continuous:             
Waist (cm) Pack-years 86.70 85.47 87.84 86.69 85.64 -0.02 -0.08,0.04  .55 0.02 -0.05, 0.09 .56 
            
Joint-Years 88.15 86.00 84.57 84.97 82.93 -0.07 -0.13, -0.01 .029 -0.08 -0.15, -0.01 .026 
            
Cannabis 
Dependence 
88.12 85.53 87.56 85.81 83.77 -0.07 -0.13, -0.01 .038 -0.08 -0.15, -0.01 .033 
             
Continuous:
High Density 
Lipoprotein 
(HDL) 
Level± 
(mmol/L) 
Pack-years 1.46 1.48 1.43 1.45 1.38 -0.06 -0.13, -0.01 .036 -0.10 -0.17, -0.03 .004 
            
Joint-Years 1.40 1.45 1.58 1.56 1.35 0.03 -0.03, 0.09 .39 0.08 0.01, 0.15 .029 
            
Cannabis 
Dependence 
1.40 1.47 1.43 1.39 1.48 0.03 -0.03, 0.09 .36 0.09 0.01, 0.16 .019 
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Table 4 Continued. 
             
  
 Statistical Testsc 
  
% or Mean  
As a Function  
of Use, Adjusted for Sexb Model 1d: Bivariate 
Model 2d: + Control for Pack-
Years (or Joint-Years) 
Age 38 Healtha Predictor 
Never 
Used 
<5 y/ 
No Dx 
5 to 
<10 y/ 
1 Dx 
10 to 
<15 y/ 
2 Dx 
15+y/ 
3+ Dx 
(RR or 
β) 95% CI p 
(RR or 
β) 95% CI p 
             
Continuous:
Triglyceride 
Level 
(mmol/L) 
Pack-years 1.99 1.99 2.08 2.27 2.22 0.07 0.01, 0.13 .021 0.11 0.04, 0.17 .002 
            
Joint-Years 2.12 2.07 1.88 1.98 1.84 -0.03 -0.09, 0.03 .38 -0.08 -0.15, -0.01 .019 
            
Cannabis 
Dependence 
2.12 2.02 2.02 2.56 1.77 -0.02 -0.08, 0.04 .51 -0.08 -0.15, -0.01 .027 
             
Continuous:
Systolic 
Blood 
Pressure (mm 
Hg) 
Pack-years 120.92 119.26 118.04 122.01 119.51 -0.02 -0.09, 0.04 .44 -0.01 -0.08, 0.06 .71 
            
Joint-Years 121.33 119.68 120.69 121.93 117.20 -0.02 -0.08, 0.04 .53 -0.01 -0.08, 0.06 .69 
            
Cannabis 
Dependence 
121.34 119.73 120.54 120.62 117.50 -0.05 -0.12, 0.01 .101 -0.06 -0.13, 0.02 .127 
             
Continuous:
Diastolic 
Blood 
Pressure (mm 
Hg) 
Pack-years 78.64 77.19 77.27 78.13 78.20 0.00 -0.06, 0.06 .98 0.01 -0.06, 0.08 .68 
            
Joint-Years 79.42 77.55 77.70 79.13 76.40 -0.01 -0.08, 0.05 .69 -0.02 -0.09, 0.05 .57 
            
Cannabis 
Dependence 
79.42 77.44 79.37 77.86 75.80 -0.06 -0.13, 0.00 .056 -0.09 -0.16, -0.01 .019 
             
             
38 
 
Table 4 Continued. 
             
  
 Statistical Testsc 
  
% or Mean  
As a Function  
of Use, Adjusted for Sexb Model 1d: Bivariate 
Model 2d: + Control for Pack-
Years (or Joint-Years) 
Age 38 Healtha Predictor 
Never 
Used 
<5 y/ 
No Dx 
5 to 
<10 y/ 
1 Dx 
10 to 
<15 y/ 
2 Dx 
15+y/ 
3+ Dx 
(RR or 
β) 95% CI p 
(RR or 
β) 95% CI p 
             
Continuous:
HbA1c 
Pack-years 5.40 5.33 5.36 5.37 5.53 0.11 0.05, 0.18 <.001 0.15 0.08, 0.23 <.001 
            
Joint-Years 5.48 5.37 5.39 5.43 5.36 0.00 -0.07, 0.06 .94 -0.08 -0.15, -0.01 .037 
            
Cannabis 
Dependence 
5.48 5.36 5.40 5.45 5.38 -0.03 -0.10, 0.03 .34 -0.13 -0.20, -0.05 .001 
             
E. Obesity             
             
Categorical:
% with Body 
Mass Index ≥ 
30 
Pack-years 24.76 23.49 31.16 21.12 22.38 0.98 0.87, 1.10 .69 1.02 0.89, 1.17 .78 
            
Joint-Years 31.20 21.98 24.54 22.88 13.70 0.90 0.79, 1.04 .154 0.89 0.76, 1.05 .169 
            
Cannabis 
Dependence 
31.23 22.19 20.57 25.64 14.43 0.85 0.74, 0.97 .021 0.82 0.70, 0.95 .010 
             
Continuous:
Body Mass 
Index (BMI) 
Pack-Years 27.50 26.80 27.89 27.30 26.32 -0.06 -0.12, 0.00 .066 -0.02 -0.10, 0.05 .51 
            
Joint-Years 28.22 26.92 26.26 26.38 25.59 -0.09 -0.15, -0.02 .011 -0.07 -0.15, 0.00 .050 
            
Cannabis 
Dependence 
28.21 26.82 27.10 26.59 25.75 -0.11 -0.17, -0.04 .002 -0.10 -0.18, -0.03 .009 
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Table 4 Continued. 
             
  
 Statistical Testsc 
  
% or Mean  
As a Function  
of Use, Adjusted for Sexb Model 1d: Bivariate 
Model 2d: + Control for Pack-
Years (or Joint-Years) 
Age 38 Healtha Predictor 
Never 
Used 
<5 y/ 
No Dx 
5 to 
<10 y/ 
1 Dx 
10 to 
<15 y/ 
2 Dx 
15+y/ 
3+ Dx 
(RR or 
β) 95% CI p 
(RR or 
β) 95% CI p 
             
F. Self-Reported 
Health 
 
     
      
             
Categorical:
% with Bad 
Health 
(rating of fair 
or poor) 
Pack-years 4.72 3.97 9.88 7.61 12.55 1.51 1.26, 1.82 <.001 1.48 1.17, 1.87 .001 
            
Joint-Years 6.34 5.79 11.35 13.04 12.77 1.26 1.06, 1.49 .010 1.04 0.83, 1.30 .75 
            
Cannabis 
Dependence 
6.32 5.19 11.31 13.60 13.16 1.28 1.03, 1.58 .023 1.01 0.78, 1.32 .92 
             
Continuous:
Mean Health 
Rating± 
Pack-years 3.97 3.96 3.72 3.70 3.43 -0.27 -0.33, -0.21 <.001 -0.26 -0.32, -0.19 <.001 
            
Joint-Years 3.86 3.88 3.53 3.46 3.47 -0.15 -0.22, -0.09 <.001 -0.03 -0.10, 0.04 .42 
            
Cannabis 
Dependence 
3.86 3.91 3.55 3.55 3.27 -0.16 -0.23, -0.10 <.001 -0.03 -0.11, 0.04 .40 
Note: COPD=chronic obstructive pulmonary disease. a. Results are presented for categorically-scored (for clinical relevance) and continuously 
scored (for greater sensitivity to variation) versions of the health measures. b. For presentation of percentages and means, participants were 
grouped according to pack-years and joint-years between ages 18-38 as follows: never used, used <5 years, used from 5 to <10 years, used from 10 
to <15 years, and used for 15+ years. Participants were grouped according to persistence of cannabis dependence as follows: never used=never 
used cannabis, no dx=used cannabis at least once between ages 18-38 but never diagnosed, 1 dx= diagnosed once between ages 18-38, 2 
dx=diagnosed twice, 3+ dx=diagnosed 3+ times. c. Statistical analyses tested associations of cumulative pack-years (a continuous variable), 
cumulative joint-years (a continuous variable), and cannabis dependence (a 5-level ordinal variable) with dichotomous and continuous outcomes. 
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Relative risks are reported for dichotomous outcomes. Beta coefficients are reported for continuous outcomes. Continuous variables were 
standardized for statistical tests. Therefore, relative risks and beta coefficients can be interpreted as the increase in risk of the outcome, given a 1 
SD increase pack-years or joint-years. Relative risks greater than 1 and betas with a positive sign indicate poorer health except where noted. ±Betas 
with a negative sign indicate poorer health. Statistically significant associations are shown in bold. d. Model 1 controls for sex. Model 2 adds 
controls for joint-years in analyses of pack-years, and adds controls for pack-years in analyses of joint-years and cannabis dependence. Analyses of 
lung function additionally control for height. For analyses of tobacco pack-years, Ns range from 892-945 for Model 1 and 886-938 for Model 2. 
For analyses of cannabis joint-years and cannabis dependence, Ns range from 888-940 for Model 1 and 886-938 for Model 2. The reasons for 
different Ns across analyses is that there was some variation in missingness for specific health measurements. Among the 947 study members 
included in this report, n=47 refused the dental exam, n=28 did not complete the lung function assessment, n=35 refused phlebotomy, 9 were 
pregnant, 6 HbA1c samples were lost in the laboratory due to the 2011 Christchurch earthquake, and there were a handful of miscellaneous assay 
failures. 
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Table 5. Within-individual change in health from age 26 to 38: associations between tobacco and cannabis use from ages 26-38 and age 38 health, 
controlling for age 26 baseline health.   
           
  Model 1: Bivariate Model 2: + Control for Baseline 
at Age 26 
Model 3b: + Control for Joint-
Years (or Pack-Years) 
     
Age 38 Healtha Exposure (RR or β) 95% CI p (RR or β) 95% CI p (RR or β) 95% CI p 
           
A. Periodontal 
Health 
          
           
Categorical:
% with 1+ 
Sites of 
>5mm 
Attachment 
Loss 
Pack-years 1.62 1.49, 1.75 <.001 1.59 1.47, 1.72 <.001 1.53 1.39, 1.69 <.001 
          
Joint-Years 1.32 1.23, 1.42 <.001 1.30 1.20, 1.40 <.001 1.08 0.98, 1.18 .110 
          
Cannabis Dependence 1.57 1.39, 1.77 <.001 1.54 1.37, 1.74 <.001 1.18 1.03, 1.36 .015 
           
Continuous:
Mean 
Attachment 
Loss Across 
Sites (mm) 
Pack-years 0.50 0.44, 0.56 <.001 0.42 0.36, 0.47 <.001 0.37 0.31, 0.43 <.001 
          
Joint-Years 0.32 0.25, 0.38 <.001 0.25 0.19, 0.31 <.001 0.10 0.05, 0.16 <.001 
          
Cannabis Dependence 0.37 0.29, 0.45 <.001 0.30 0.23, 0.38 <.001 0.11 0.04, 0.19 .002 
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Table 5 Continued. 
           
  Model 1: Bivariate Model 2: + Control for Baseline 
at Age 26 
Model 3b: + Control for Joint-
Years (or Pack-Years) 
     
Age 38 Healtha Exposure (RR or β) 95% CI p (RR or β) 95% CI p (RR or β) 95% CI p 
           
B. Lung 
Function 
          
           
Categorical:
% with 
COPD 
(FEV1/FVC     
< 70) 
Pack-years 1.27 1.02, 1.57 .030 1.27 1.05, 1.55 .015 1.33 1.10, 1.62 .004 
          
Joint-Years 1.13 0.92, 1.39 .24 1.01 0.84, 1.20 .93 0.91 0.78, 1.06 .22 
          
Cannabis Dependence 1.20 0.92, 1.56 .178 1.18 0.92, 1.53 .199 1.03 0.80, 1.33 .81 
           
Continuous:
FEV1/FVC
±  
Pack-years -0.19 -0.26, -0.12 <.001 -0.14 -0.19, -0.10 <.001 -0.11 -0.16, -0.06 <.001 
          
Joint-Years -0.15 -0.21, -0.08 <.001 -0.11 -0.16, -0.07 <.001 -0.07 -0.12, -0.02 .008 
          
Cannabis Dependence -0.17 -0.26, -0.09 <.001 -0.14 -0.20, -0.09 <.001 -0.08 -0.15, -0.02 .011 
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Table 5 Continued. 
           
  Model 1: Bivariate Model 2: + Control for Baseline 
at Age 26 
Model 3b: + Control for Joint-
Years (or Pack-Years) 
     
Age 38 Healtha Exposure (RR or β) 95% CI p (RR or β) 95% CI p (RR or β) 95% CI p 
           
C. Systemic 
Inflammation 
          
           
Categorical:
% with High 
C-Reactive 
Protein (>3 
mg/L) 
Pack-years 1.16 1.02, 1.31 .026 1.16 1.03, 1.32 .019 1.11 0.97, 1.28 .135 
          
Joint-Years 1.14 1.01, 1.29 .038 1.16 1.03, 1.32 .017 1.11 0.97, 1.28 .145 
          
Cannabis Dependence 1.17 0.97, 1.40 .093 1.21 1.00, 1.46 .050 1.13 0.92, 1.38 .25 
           
Continuous:
C-Reactive 
Protein Level 
(mg/L) 
Pack-years 0.11 0.04, 0.18 .003 0.11 0.04, 0.17 .002 0.09 0.01, 0.16 .021 
          
Joint-Years 0.08 0.01, 0.16 .026 0.09 0.02, 0.16 .013 0.05 -0.03, 0.13 .199 
          
Cannabis Dependence 0.02 -0.07, 0.12 .61 0.04 -0.05, 0.13 .38 -0.02 -0.12, 0.07 .62 
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Table 5 Continued. 
           
  Model 1: Bivariate Model 2: + Control for Baseline 
at Age 26 
Model 3b: + Control for Joint-
Years (or Pack-Years) 
     
Age 38 Healtha Exposure (RR or β) 95% CI p (RR or β) 95% CI p (RR or β) 95% CI p 
           
D. Metabolic 
Health 
          
           
Categorical: 
% with 
Metabolic 
Syndrome 
Pack-years 1.18 1.03, 1.36 .020 1.18 1.02, 1.35 .021 1.21 1.04, 1.41 .014 
          
Joint-Years 1.00 0.86, 1.16 .99 1.01 0.88, 1.17 .88 0.93 0.79, 1.10 .41 
          
Cannabis Dependence 1.02 0.84, 1.26 .80 1.07 0.88, 1.31 .50 0.98 0.79, 1.21 .84 
           
E. Obesity           
           
Categorical:
% with Body 
Mass Index ≥ 
30 
Pack-years 0.96 0.84, 1.09 .49 0.96 0.86, 1.08 .49 1.00 0.89, 1.12 .99 
          
Joint-Years 0.88 0.76, 1.01 .073 0.91 0.80, 1.05 .21 0.91 0.79, 1.06 .24 
          
Cannabis Dependence 0.84 0.71, 0.99 .047 0.92 0.79, 1.07 .27 0.93 0.80, 1.09 .37 
           
Continuous:
Body Mass 
Index (BMI) 
Pack-Years -0.07 -0.14, -0.01 .027 0.00 -0.04, 0.04 .91 0.02 -0.03, 0.06 .51 
          
Joint-Years -0.09 -0.16, -0.03 .006 -0.02 -0.06, 0.02 .35 -0.03 -0.07, 0.02 .25 
          
Cannabis Dependence -0.13 -0.21, -0.04 .004 -0.01 -0.07, 0.04 .60 -0.01 -0.07, 0.04 .59 
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Table 5 Continued. 
           
  Model 1: Bivariate Model 2: + Control for Baseline 
at Age 26 
Model 3b: + Control for Joint-
Years (or Pack-Years) 
     
Age 38 Healtha Exposure (RR or β) 95% CI p (RR or β) 95% CI p (RR or β) 95% CI p 
           
F. Self-Reported 
Health 
          
           
Categorical:
% with Bad 
Health 
(rating of fair 
or poor) 
Pack-years 1.54 1.29, 1.84 <.001 1.37 1.11, 1.70 .004 1.37 1.08, 1.73 .010 
          
Joint-Years 1.14 0.94, 1.40 .192 1.08 0.87, 1.33 .49 0.96 0.78, 1.19 .72 
          
Cannabis Dependence 1.26 0.94, 1.69 .118 1.17 0.88, 1.55 .29 1.00 0.73, 1.37 .99 
           
Continuous:
Mean Health 
Rating± 
Pack-years -0.27 -0.33, -0.21 <.001 -0.16 -0.22, -0.10 <.001 -0.16 -0.22, -0.10 <.001 
          
Joint-Years -0.11 -0.18, -0.05 <.001 -0.06 -0.11, 0.00 .064 0.01 -0.05, 0.07 .77 
          
Cannabis Dependence -0.17 -0.26, -0.09 <.001 -0.12 -0.19, -0.04 .002 -0.04 -0.12, 0.04 .34 
Note. COPD=chronic obstructive pulmonary disease. a. Results are presented for categorically-scored (for clinical relevance) and continuously scored 
(for greater sensitivity to variation) versions of the health measures. b. Model 3 adds controls for joint-years in analyses of pack-years, and adds 
controls for pack-years in analyses of joint-years and cannabis dependence. Statistical analyses tested associations of cumulative pack-years (a 
continuous variable), cumulative joint-years (a continuous variable), and cannabis dependence (a 5-level ordinal variable) with dichotomous and 
continuous outcomes. Relative risks are reported for dichotomous outcomes. Beta coefficients are reported for continuous outcomes. Continuous 
variables were standardized for statistical tests. Therefore, relative risks and beta coefficients can be interpreted as the increase in risk of the outcome, 
given a 1 SD increase in pack-years or joint-years. Relative risks greater than 1 and betas with a positive sign indicate poorer health except where 
noted. ±Betas with a negative sign indicate poorer health. Statistically significant associations are shown in bold. All models control for sex. Analyses 
of lung function additionally control for height. 
 
 
 
